1-20 of 23
Karen Liby
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 529: Novel inhibitors of the NRF2 pathway also arrest lung cancer cells in G2/M

Free
Christopher John Occhiuto, Lizbeth Lockwood, Zhilin Hou, Aaron Odom, Karen Liby
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 529.
https://doi.org/10.1158/1538-7445.AM2023-529
Published: 04 April 2023
View article titled, Abstract 529: Novel inhibitors of the NRF2 pathway also arrest lung cancer cells in G2/M
Journal Articles

Abstract 1118: The novel rexinoid V-125 reduces tumor growth in the MMTV-Neu model of breast cancer and the A/J model of lung cancer via immunomodulation

Free
Lyndsey Reich, Jessica Moerland, Ana S. Leal, Di Zhang, Sarah Carapellucci, Carl E. Wagner, Karen Liby
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1118.
https://doi.org/10.1158/1538-7445.AM2022-1118
Published: 15 June 2022
View article titled, Abstract 1118: The novel rexinoid V-125 reduces tumor growth in the MMTV-Neu model of breast cancer and the A/J model of lung cancer via immunomodulation
Journal Articles

Abstract 12: Localized delivery of the PARP inhibitor Talazoparib for chemoprevention of breast cancer

Free
Di Zhang, Bijay Singh, Jessica Moerland, Owen Mitchell, Lizbeth Lockwood, Sarah Carapellucci, Srinivas Sridhar, Karen Liby
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 12.
https://doi.org/10.1158/1538-7445.AM2020-12
Published: 15 August 2020
View article titled, Abstract 12: Localized delivery of the PARP inhibitor Talazoparib for chemoprevention of breast cancer
Journal Articles

Abstract 1: A small molecule inhibits Nrf2 expression and activity in cancer cells

Free
Di Zhang, Corbin Livingston, Thomas Dexheimer, Edmund Ellsworth, Aaron Odom, Karen Liby
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1.
https://doi.org/10.1158/1538-7445.AM2019-1
Published: 01 July 2019
View article titled, Abstract 1: A small molecule inhibits Nrf2 expression and activity in cancer cells
Journal Articles

Abstract 3874: Developing a nanoformulation of the PARP inhibitor talazoparib as a novel delivery for treatment of BRCA-deficient breast cancer

Free
Di Zhang, Paige Baldwin, Srinivas Sridhar, Karen Liby
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3874.
https://doi.org/10.1158/1538-7445.AM2018-3874
Published: 01 July 2018
View article titled, Abstract 3874: Developing a nanoformulation of the PARP inhibitor talazoparib as a novel delivery for treatment of BRCA-deficient breast cancer
Journal Articles

Abstract 4051: Different immune signatures in advanced lung tumors of Nrf2 wildtype vs. knockout mice

Free
Di Zhang, Jonathan Rennhack, Eran Andrechek, Cheryl Rockwell, Karen Liby
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4051.
https://doi.org/10.1158/1538-7445.AM2018-4051
Published: 01 July 2018
View article titled, Abstract 4051: Different immune signatures in advanced lung tumors of Nrf2 wildtype vs. knockout mice
Journal Articles

Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery

Free
Paige Baldwin, Rajiv Kumar, Edward Favours, Karen Liby, Raushan Kurmasheva, David Kozono, Srinivas Sridhar
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3100.
https://doi.org/10.1158/1538-7445.AM2017-3100
Published: 01 July 2017
View article titled, Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery
Journal Articles

Abstract B30: Sustained release of PARP inhibitor Talazoparib and chemotherapeutic Docetaxel from modified brachytherapy spacers for treatment of breast and prostate cancer

Free
Jodi Belz, Noelle Castilla Ojo, Paige Baldwin, Rajiv Kumar, Anne van de Ven, Karen Liby, Robert Cormack, Mike Makrigiorgos, Srinivas Sridhar
Journal: Cancer Research
Cancer Res (2017) 77 (2_Supplement): B30.
https://doi.org/10.1158/1538-7445.EPSO16-B30
Published: 16 January 2017
View article titled, Abstract B30: Sustained release of PARP inhibitor Talazoparib and chemotherapeutic Docetaxel from modified brachytherapy spacers for treatment of breast and prostate cancer
Journal Articles

Abstract B29: Nanoformulations and sustained delivery systems for the PARP inhibitors Olaparib and Talazoparib

Free
Paige Baldwin, Anders Ohman, Jodi Belz, Jeremy Thong, Noelle Castilla Ojo, Karen Liby, Daniela Dinulescu, Srinivas Sridhar
Journal: Cancer Research
Cancer Res (2017) 77 (2_Supplement): B29.
https://doi.org/10.1158/1538-7445.EPSO16-B29
Published: 16 January 2017
View article titled, Abstract B29: Nanoformulations and sustained delivery systems for the PARP inhibitors Olaparib and Talazoparib
Journal Articles

Abstract 3900: Sustained release of PARP inhibitor Talazoparib and chemotherapeutics from biodegradable implants for treatment of breast and prostate cancer

Free
Jodi Belz, Noelle Castilla Ojo, Paige Baldwin, Rajiv Kumar, Anne van de Ven, Karen Liby, Robert Cormack, Mike Makrigiorgos, Srinivas Sridhar
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3900.
https://doi.org/10.1158/1538-7445.AM2016-3900
Published: 15 July 2016
View article titled, Abstract 3900: Sustained release of PARP inhibitor Talazoparib and chemotherapeutics from biodegradable implants for treatment of breast and prostate cancer
Journal Articles

Abstract 5559: Novel synthetic pyridyl analogues of CDDO-Im with improved stability and their potential use in cancer prevention

Free
Martine Cao, Evans Onyango, Charlotte Williams, Darlene Royce, Gordon Gribble, Michael Sporn, Karen Liby
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 5559.
https://doi.org/10.1158/1538-7445.AM2015-5559
Published: 01 August 2015
View article titled, Abstract 5559: Novel synthetic pyridyl analogues of CDDO-Im with improved stability and their potential use in cancer prevention
Journal Articles

Abstract B22: The evaluation of the synthetic triterpenoid CDDO-ethyl amide and the histone deacetylase inhibitor vorinostat for prevention of pancreatic cancer .

Free
Karen Liby, Darlene Royce, Charlotte Williams, Renee Risingsong, Kim Tran
Journal: Cancer Research
Cancer Res (2012) 72 (14_Supplement): B22.
https://doi.org/10.1158/1538-7445.PANCA2012-B22
Published: 03 April 2014
View article titled, Abstract B22: The evaluation of the synthetic triterpenoid CDDO-ethyl amide and the histone deacetylase inhibitor vorinostat for prevention of pancreatic cancer .
Journal Articles

Abstract 180: Inhibition of tumorigenesis by a novel Gemini vitamin D analog BXL0124 and a synthetic triterpenoid CDDO-Im in MMTV-HER2/neu transgenic mice.

Free
Jae Young So, Amanda K. Smolarek, Hubert Maehr, Milan Uskokovic, Karen Liby, Michael B. Sporn, Nanjoo Suh
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 180.
https://doi.org/10.1158/1538-7445.AM2013-180
Published: 15 April 2013
View article titled, Abstract 180: Inhibition of tumorigenesis by a novel Gemini vitamin D analog BXL0124 and a synthetic triterpenoid CDDO-Im in MMTV-HER2/neu transgenic mice.
Journal Articles

ΔNp63α-Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells

Free
Amanda L. Balboni, Justine A. Hutchinson, Andrew J. DeCastro, Pratima Cherukuri, Karen Liby, Michael B. Sporn, Gary N. Schwartz, Wendy A. Wells, Lorenzo F. Sempere, Paul B. Yu, James DiRenzo
Journal: Cancer Research
Cancer Res (2013) 73 (2): 1020–1030.
https://doi.org/10.1158/0008-5472.CAN-12-2862
Published: 16 January 2013
View article titled, ΔNp63α-Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells
Open the PDF for ΔNp63α-Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells in another window
Journal Articles

Abstract 820: The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, and the histone deacetylase inhibitor vorinostat delay carcinogenesis in a transgenic model of estrogen receptor-negative breast cancer

Free
Kim M. Tran, Michael B. Sporn, Karen Liby
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 820.
https://doi.org/10.1158/1538-7445.AM2011-820
Published: 15 April 2011
View article titled, Abstract 820: The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, and the histone deacetylase inhibitor vorinostat delay carcinogenesis in a transgenic model of estrogen receptor-negative breast cancer
Journal Articles

A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin

Free
Karen Liby, Mark M. Yore, Bill D. Roebuck, Karen J. Baumgartner, Tadashi Honda, Chitra Sundararajan, Hidenori Yoshizawa, Gordon W. Gribble, Charlotte R. Williams, Renee Risingsong, Darlene B. Royce, Albena T. Dinkova-Kostova, Katherine K. Stephenson, Patricia A. Egner, Melinda S. Yates, John D. Groopman, Thomas W. Kensler, Michael B. Sporn
Journal: Cancer Research
Cancer Res (2008) 68 (16): 6727–6733.
https://doi.org/10.1158/0008-5472.CAN-08-1123
Published: 12 August 2008
View article titled, A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin
Open the PDF for A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin in another window
Journal Articles

Novel angio-preventive molecules and mechanisms: A focus on synthetic triterpenoids CDDO

Free
Adriana Albini, Nicola Vannini, Girieca Lorusso, Francesca Tosetti, Nicoletta Ferrari, Roberto Benelli, Ulrich Pfeffer, Ilaria Sogno, Karen Liby, Michael Sporn, Douglas Noonan
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3389.
Published: 01 May 2007
View article titled, Novel angio-preventive molecules and mechanisms: A focus on synthetic triterpenoids CDDO
Journal Articles

The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice

Free
Karen Liby, Darlene B. Royce, Charlotte R. Williams, Renee Risingsong, Mark M. Yore, Tadashi Honda, Gordon W. Gribble, Ethan Dmitrovsky, Thomas A. Sporn, Michael B. Sporn
Journal: Cancer Research
Cancer Res (2007) 67 (6): 2414–2419.
https://doi.org/10.1158/0008-5472.CAN-06-4534
Published: 15 March 2007
View article titled, The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice
Open the PDF for The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice in another window
Journal Articles

A synthetic triterpenoid CDDO-Im induces monocytic differentiation by activating Smad signaling pathway in HL60 leukemia cells

Free
Yan Ji, Hong Jin Lee, Catherine Goodman, Milan Uskokovic, Karen Liby, Michael Sporn, Nanjoo Suh
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 571.
Published: 15 April 2006
View article titled, A synthetic triterpenoid CDDO-Im induces monocytic differentiation by activating Smad signaling pathway in HL60 leukemia cells
Journal Articles

The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling

Free
Karen Liby, Thomas Hock, Mark M. Yore, Nanjoo Suh, Andrew E. Place, Renee Risingsong, Charlotte R. Williams, Darlene B. Royce, Tadashi Honda, Yukiko Honda, Gordon W. Gribble, Nathalie Hill-Kapturczak, Anupam Agarwal, Michael B. Sporn
Journal: Cancer Research
Cancer Res (2005) 65 (11): 4789–4798.
https://doi.org/10.1158/0008-5472.CAN-04-4539
Published: 01 June 2005
View article titled, The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling
Open the PDF for The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling in another window